Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

OBJECTIVE: To determine whether baclofen can suppress the cough induced by angiotensin-converting enzyme (ACE) inhibitors. DESIGN: Prospective, open label, clinical trial of a 4 week course of low-dose oral baclofen (5 mg tid days 1-7, 10 mg tid days 8-28). SUBJECTS: Seven patients with severe, persistent ACE inhibitor-induced cough. SETTING: University-affiliated teaching hospital. MAIN OUTCOME MEASURES: Study participants kept daily diaries monitoring the frequency of cough during and after completion of baclofen therapy. RESULTS: All subjects demonstrated diminution of cough after initiation of baclofen. Initial improvement was noted by a mean of 4.0 days (range 3-6), and maximal improvement during treatment was achieved by a mean of 10.7 days (range 5-15). In addition, all subjects demonstrated persistent suppression of cough (range 25-74 d) after discontinuation of the study drug. CONCLUSION: Low-dose oral baclofen therapy caused a prolonged antitussive effect in all subjects without inducing any adverse reactions. Baclofen may offer an alternative to the discontinuation of ACE inhibitor therapy in patients for whom these drugs are required.

Original languageEnglish (US)
Pages (from-to)1242-1245
Number of pages4
JournalAnnals of Pharmacotherapy
Volume30
Issue number11
StatePublished - Nov 1996

Fingerprint

Baclofen
Angiotensin-Converting Enzyme Inhibitors
Cough
Antitussive Agents
Enzyme Therapy
Teaching Hospitals
Pharmaceutical Preparations
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. / Dicpinigaitis, Peter Vytautas.

In: Annals of Pharmacotherapy, Vol. 30, No. 11, 11.1996, p. 1242-1245.

Research output: Contribution to journalArticle

@article{a642fd922eb24c3ea24d5f8456d19e55,
title = "Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors",
abstract = "OBJECTIVE: To determine whether baclofen can suppress the cough induced by angiotensin-converting enzyme (ACE) inhibitors. DESIGN: Prospective, open label, clinical trial of a 4 week course of low-dose oral baclofen (5 mg tid days 1-7, 10 mg tid days 8-28). SUBJECTS: Seven patients with severe, persistent ACE inhibitor-induced cough. SETTING: University-affiliated teaching hospital. MAIN OUTCOME MEASURES: Study participants kept daily diaries monitoring the frequency of cough during and after completion of baclofen therapy. RESULTS: All subjects demonstrated diminution of cough after initiation of baclofen. Initial improvement was noted by a mean of 4.0 days (range 3-6), and maximal improvement during treatment was achieved by a mean of 10.7 days (range 5-15). In addition, all subjects demonstrated persistent suppression of cough (range 25-74 d) after discontinuation of the study drug. CONCLUSION: Low-dose oral baclofen therapy caused a prolonged antitussive effect in all subjects without inducing any adverse reactions. Baclofen may offer an alternative to the discontinuation of ACE inhibitor therapy in patients for whom these drugs are required.",
author = "Dicpinigaitis, {Peter Vytautas}",
year = "1996",
month = "11",
language = "English (US)",
volume = "30",
pages = "1242--1245",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "11",

}

TY - JOUR

T1 - Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors

AU - Dicpinigaitis, Peter Vytautas

PY - 1996/11

Y1 - 1996/11

N2 - OBJECTIVE: To determine whether baclofen can suppress the cough induced by angiotensin-converting enzyme (ACE) inhibitors. DESIGN: Prospective, open label, clinical trial of a 4 week course of low-dose oral baclofen (5 mg tid days 1-7, 10 mg tid days 8-28). SUBJECTS: Seven patients with severe, persistent ACE inhibitor-induced cough. SETTING: University-affiliated teaching hospital. MAIN OUTCOME MEASURES: Study participants kept daily diaries monitoring the frequency of cough during and after completion of baclofen therapy. RESULTS: All subjects demonstrated diminution of cough after initiation of baclofen. Initial improvement was noted by a mean of 4.0 days (range 3-6), and maximal improvement during treatment was achieved by a mean of 10.7 days (range 5-15). In addition, all subjects demonstrated persistent suppression of cough (range 25-74 d) after discontinuation of the study drug. CONCLUSION: Low-dose oral baclofen therapy caused a prolonged antitussive effect in all subjects without inducing any adverse reactions. Baclofen may offer an alternative to the discontinuation of ACE inhibitor therapy in patients for whom these drugs are required.

AB - OBJECTIVE: To determine whether baclofen can suppress the cough induced by angiotensin-converting enzyme (ACE) inhibitors. DESIGN: Prospective, open label, clinical trial of a 4 week course of low-dose oral baclofen (5 mg tid days 1-7, 10 mg tid days 8-28). SUBJECTS: Seven patients with severe, persistent ACE inhibitor-induced cough. SETTING: University-affiliated teaching hospital. MAIN OUTCOME MEASURES: Study participants kept daily diaries monitoring the frequency of cough during and after completion of baclofen therapy. RESULTS: All subjects demonstrated diminution of cough after initiation of baclofen. Initial improvement was noted by a mean of 4.0 days (range 3-6), and maximal improvement during treatment was achieved by a mean of 10.7 days (range 5-15). In addition, all subjects demonstrated persistent suppression of cough (range 25-74 d) after discontinuation of the study drug. CONCLUSION: Low-dose oral baclofen therapy caused a prolonged antitussive effect in all subjects without inducing any adverse reactions. Baclofen may offer an alternative to the discontinuation of ACE inhibitor therapy in patients for whom these drugs are required.

UR - http://www.scopus.com/inward/record.url?scp=0029910150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029910150&partnerID=8YFLogxK

M3 - Article

C2 - 8913404

AN - SCOPUS:0029910150

VL - 30

SP - 1242

EP - 1245

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 11

ER -